Remo Moomiaie-Qajar

Axiom Biosciences, a San Diego-based clinical-stage biotech, plans a Hong Kong IPO in 2027 targeting at least $200 million, followed by a U.S. secondary listing in 2029, citing deep biotechnology capi…

Axiom Biosciences, a US biotech firm using AI to develop therapies for newborns with severe brain injuries, plans to raise at least US$200 million through an IPO in Hong Kong in 2027, followed by a se…